MCP-1 and MIP3-alpha serum levels in acute liver failure and molecular adsorbent recirculating system (MARS) treatment: A pilot study

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 6, 2009, Pages 745-751

  Roth, Georg A ^a,c   Faybik, Peter ^a   Hetz, Hubert ^a   Ankersmit, Hendrik J ^b   Hoetzenecker, Konrad ^b   Bacher, Andreas ^a   Thalhammer, Theresia ^c   Krenn, Claus G ^a  

^a Department of Anaesthesiology

^b Department of Cardiothoracic Surgery ^*

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acute liver failure; Acute on chronic liver failure; Chemokines; MARS; MCP 1; MIP3 alpha

Indexed keywords

BETA CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGED; ALBUMIN DIALYSIS; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE; LIVER FUNCTION; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHEMOKINE CCL20; FEMALE; HUMANS; LIVER FAILURE, ACUTE; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 67651156305     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520902770086     Document Type: Article

References (31)

1. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179-97.
2. Rinella ME, Sanyal A. Intensive management of hepatic failure. Semin Respir Crit Care Med 2006;27:241-61.
3. Schmidt LE, Sorensen VR, Svendsen LB, Hansen BA, Larsen FS. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 2001;7:1034-9.
4. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003;9:290-7.
5. Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004;10:1109-19.
6. Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 2005;100:468-75.
7. Steiner C, Sen S, Stange J, Williams R, Jalan R. Binding of bilirubin and bromosulphthalein to albumin: implications for understanding the pathophysiology of liver failure and its management. Liver Transpl 2004;10:1531-8.
8. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36:949-58.
9. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-86.
10. Leifeld L, Dumoulin FL, Purr I, Janberg K, Trautwein C, Wolff M, et al. Early up-regulation of chemokine expression in fulminant hepatic failure. J Pathol 2003;199:335-44.
11. Leifeld L, Trautwein C, Dumoulin FL, Manns MP, Sauerbruch T, Spengler U. Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol 1999;154: 1711-20.
12. Rollins BJ. Chemokines. Blood 1997;90:909-28.
13. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003;14:409-26.
14. Yamauchi K, Akbar SM, Horiike N, Michitaka K, Onji M. Increased serum levels of macrophage inflammatory protein-3alpha in chronic viral hepatitis: prognostic importance of macrophage inflammatory protein-3alpha during interferon therapy in chronic hepatitis C. J Viral Hepat 2002;9:213-20.
15. Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, Koukoudis P, et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 2002;17: 435.
16. Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002;26:103-10.
17. Faybik P, Bacher A, Kozek-Langenecker SA, Steltzer H, Krenn CG, Unger S, et al. Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study. Crit Care 2006;10:R24.
18. Miyake Y, Iwasaki Y, Terada R, Takaguchi K, Sakaguchi K, Shiratori Y Systemic inflammatory response syndrome strongly affects the prognosis of patients with fulminant hepatitis B. J Gastroenterol 2007;42:485-92.
19. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32:734-9.
20. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004;40:247-54.
21. Simpson KJ, Henderson NC, Bone-Larson CL, Lukacs NW, Hogaboam CM, Kunkel SL. Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. Clin Sci (Lond) 2003;104:47-63.
22. Yamaguchi Y, Matsumura F, Liang J, Okabe K, Ohshiro H, Ishihara K, et al. Neutrophil elastase and oxygen radicals enhance monocyte chemoattractant protein-1 expression after ischemia/reperfusion in rat liver. Transplantation 1999;68:1459-68.
23. Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Strieter RM, Kunkel SL. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J Immunol 1999;163:6148-54.
24. Marra F, DeFranco R, Grappone C, Parola M, Milani S, Leonarduzzi G, et al. Expression of monocyte chemotactic protein-1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E. J Invest Med 1999;47:/66-75.
25. Yamaguchi M, Gabazza EC, Taguchi O, Yano Y, Ikoma J, Kaito M, et al. Decreased protein C activation in patients with fulminant hepatic failure. Scand J Gastroenterol 2006; 41:331-7.
26. Shimizu Y, Murata H, Kashii Y, Hirano K, Kunitani H, Higuchi K, et al. CC-chemokine receptor 6 and its ligand macrophage inflammatory protein 3alpha might be involved in the amplification of local necroinflammatory response in the liver. Hepatology 2001;34:311-9.
27. Ankersmit HJ, Deicher R, Moser B, Teufel I, Roth G, Gerlitz S, et al. Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol 2001;125:142-8.
28. Ankersmit HJ, Tugulea S, Spanier T, Weinberg AD, Artrip JH, Burke EM, et al. Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet 1999;354:550-5.
29. Akahoshi T, Kobayashi N, Hosaka S, Sekiyama N, Wada C, Kondo H. In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure. Nephrol Dial Transplant 1995;10:2244-9.
30. Kiyici S, Erturk E, Budak F, Ersoy C, Tuncel E, Duran C et al. Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic patients with nephropathy. Arch Med Res 2006;37:998-1003.
31. Rovin BH, Doe N, Tan LC. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 1996;27:640-6.